Immunological mediated therapies for heart failure

Israel Medical Association Journal

Volumn 11, Issue 5, 2009, Pages 301-305

  Blum, Arnon ^a  

^a Baruch Padeh Poria Medical Center   (Israel)

Author keywords

Congestive heart failure; Immune modulation; Immune therapy; Immunoadsorption therapy; Thalidomide

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PLACEBO; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DROWSINESS; DRUG DOSE REDUCTION; DRUG RESPONSE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SUBSTITUTION THERAPY;

HEART FAILURE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSORBENTS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649208909     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Gullestad L, Ueland T, Brunsvig A, et al. Effect of metoprolol on cytokine levels in chronic heart failure - a substudy in the MERIT-HF trial. Am Heart J 2001; 141: 418-21.
2. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-6.
3. Anker SD, Voats AJS. How to recover from RENAISSANCE? The significance of the results from RECOVER, RENAISSANCE, RNEWAL and ATTACH. Int J Cardiol 2002; 86: 123-30.
4. Kadokami T, McTiernan CF, Kubota T, et al. Effects of soluble TNF receptor treatment on lipopolysacharide induced myocardial cytokine expression. Am J Physiol 2001; 280: H2281-91.
5. Tore-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
6. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-71.
7. Deveaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 18: 470-9.
8. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-9.
9. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha induced apoptosis in cardiac myocytes. J Clin Invest 1996; 98: 2854-65.
10. Bozkurt B, Kribbs SB, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor alpha promote progressive dysfunction and remodeling in rats. Circulation 1998; 97: 1382-91.
11. Mobini N, Sarela A, Ahmed AR. Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 1995; 74: 119-28.
12. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95: 2476-8.
13. Ballow M. Mechanism of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997; 100: 151-7.
14. Aukrust P, Froland SS, Liabakk NK, et al. Release of cytokines, soluble cytokine receptors and interleukin 1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136-43.
15. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
16. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
17. Damas JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure - modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 38 (1): 187-93.
18. Babei S, Stewart DJ, Picard P, Monge JC. Effects of VasoCare therapy on the initiation and progression of atherosclerosis. Atherosclerosis 2002; 162: 45-53.
19. Nolan Y, Minogue A, Veneker E, et al. Attenuation of LPS induced changes in synaptic activity in rat hippocampus by Vasogen's immune modulation therapy (IMT) improves postischemic foot skin blood flow and transcutaneous pO(2) recovery rates in patients with advanced peripheral arterial occlusive disease. Int Angiol 2003; 22: 141-7.
20. McGrath C, Robb R, Lucas AJ, et al. A randomized, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. Eur J Vasc Endovasc Surg 2002; 23: 381-7.
21. Torre-Amione G, Sestier F, Radovancevic B, Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure. J Am Coll Cardiol 2004; 44: 1181-6.
22. Torre-Amione G, Maclellan W, Kapadia D, et al. Tumor necrosis factor alpha is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. Transplant Proc 1998; 30: 875-7.
23. Torre-Amione G, Amker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomized trial. Lancet 2008; 371: 228-36.
24. Limas CJ, Goldenberg IF, Limas C. Soluble interleukin 2 receptor levels in patients with dilated cardiomyopathy: correlation with disease severity and cardiac autoantibodies. Circulation 1995; 91: 631-4.
25. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell mediated disease. J Immunol 1991; 147: 2141-7.
26. Schulze K, Becker BF, Schauer R, et al. Antibodies to ADP-ATP carrier - an autoantigen in myocarditis and dilated cardiomyopathy - impair cardiac function. Circulation 1990; 81: 959-69.
27. Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha and beta cardiac myosin chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734-42.
28. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the beta 1 adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760-7.
29. Dorffel WV, Felix SB, Wallukat G, et al. Short term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997; 95: 1994-7.
30. Felix S, Staudt A, Dorffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590-8.
31. Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001; 103: 2681-8.
32. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
33. Agoston I, Dibbs ZI, Wang F, et al. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Cardiac Fail 2002; 8(5): 306-14.
34. Gullestad L, Semb AG, Holt E, et al. Effect of thalidomide in patients with chronic heart failure. Am Heart J 2002; 144 (5): 847-50.
35. Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure. Circulation 2005; 112: 3408-14.